fig5

Figure 5. CD147-enriched sEVs regulate HUVECs angiogenesis by activating the PI3K/Akt pathway. (A, B) HUVECs were treated with sEVs for 24 h followed by western blot analysis using antibodies as indicated (A) and quantification of protein levels as shown in (A) (B). Molecular weight is indicated on the right; (C-F): (C) HUVECs were treated with PBS, HepG2-WT-sEVs, HepG2-CD147(KD)-sEVs, and MK-2206, followed by adding HepG2-WT-sEVs, respectively. The treated cells were analyzed for proliferation (treatment time: 24 h); (D) wound healing (treatment time: 48 h); (E) migration (treatment time: 24 h); (F) tube formation (treatment time: 6 h). Original magnification of image: × 40. ***: P < 0.001; ****: P < 0.0001; EVs: extracellular vesicles; HUVECs: human umbilical vein endothelial cells.